Compare VENUS REMEDIES with Biocon - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs BIOCON - Comparison Results

BIOCON  
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES BIOCON VENUS REMEDIES/
BIOCON
 
P/E (TTM) x -13.9 34.0 - View Chart
P/BV x 0.9 4.1 22.8% View Chart
Dividend Yield % 0.0 0.2 -  

Financials

 VENUS REMEDIES   BIOCON
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-18
BIOCON
Mar-19
VENUS REMEDIES/
BIOCON
5-Yr Chart
Click to enlarge
High Rs126707 17.8%   
Low Rs61554 11.0%   
Sales per share (Unadj.) Rs301.891.9 328.4%  
Earnings per share (Unadj.) Rs-24.916.7 -148.8%  
Cash flow per share (Unadj.) Rs2.524.2 10.5%  
Dividends per share (Unadj.) Rs01.00 0.0%  
Dividend yield (eoy) %00.2 0.0%  
Book value per share (Unadj.) Rs293.3101.6 288.6%  
Shares outstanding (eoy) m12.34600.00 2.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.36.9 4.5%   
Avg P/E ratio x-3.837.7 -10.0%  
P/CF ratio (eoy) x36.726.1 140.9%  
Price / Book Value ratio x0.36.2 5.1%  
Dividend payout %06.0 0.0%   
Avg Mkt Cap Rs m1,154378,330 0.3%   
No. of employees `0000.96.1 15.1%   
Total wages/salary Rs m39311,653 3.4%   
Avg. sales/employee Rs Th4,026.18,994.3 44.8%   
Avg. wages/employee Rs Th425.01,900.7 22.4%   
Avg. net profit/employee Rs Th-331.81,635.3 -20.3%   
INCOME DATA
Net Sales Rs m3,72455,144 6.8%  
Other income Rs m231,444 1.6%   
Total revenues Rs m3,74756,588 6.6%   
Gross profit Rs m39515,883 2.5%  
Depreciation Rs m3384,478 7.6%   
Interest Rs m354709 50.0%   
Profit before tax Rs m-27512,140 -2.3%   
Minority Interest Rs m09 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m322,123 1.5%   
Profit after tax Rs m-30710,026 -3.1%  
Gross profit margin %10.628.8 36.8%  
Effective tax rate %-11.517.5 -65.6%   
Net profit margin %-8.218.2 -45.3%  
BALANCE SHEET DATA
Current assets Rs m2,63848,228 5.5%   
Current liabilities Rs m2,30530,376 7.6%   
Net working cap to sales %8.932.4 27.6%  
Current ratio x1.11.6 72.1%  
Inventory Days Days13568 198.3%  
Debtors Days Days4686 54.2%  
Net fixed assets Rs m4,87164,130 7.6%   
Share capital Rs m1233,000 4.1%   
"Free" reserves Rs m3,49657,980 6.0%   
Net worth Rs m3,61960,980 5.9%   
Long term debt Rs m1,37415,766 8.7%   
Total assets Rs m7,509121,924 6.2%  
Interest coverage x0.218.1 1.2%   
Debt to equity ratio x0.40.3 146.9%  
Sales to assets ratio x0.50.5 109.7%   
Return on assets %0.68.8 7.2%  
Return on equity %-8.516.4 -51.6%  
Return on capital %1.616.8 9.4%  
Exports to sales %028.1 0.0%   
Imports to sales %13.918.9 73.6%   
Exports (fob) Rs mNA15,506 0.0%   
Imports (cif) Rs m51710,399 5.0%   
Fx inflow Rs m015,506 0.0%   
Fx outflow Rs m51710,399 5.0%   
Net fx Rs m-5175,107 -10.1%   
CASH FLOW
From Operations Rs m51411,546 4.5%  
From Investments Rs m-123-7,138 1.7%  
From Financial Activity Rs m-387-2,417 16.0%  
Net Cashflow Rs m42,103 0.2%  

Share Holding

Indian Promoters % 32.9 40.4 81.3%  
Foreign collaborators % 0.0 20.6 -  
Indian inst/Mut Fund % 0.2 8.4 2.1%  
FIIs % 0.6 10.7 5.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 19.9 333.7%  
Shareholders   20,121 109,995 18.3%  
Pledged promoter(s) holding % 36.4 0.0 90,900.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   FULFORD INDIA  AUROBINDO PHARMA  STERLING BIOTECH  WOCKHARDT  SUN PHARMA  

Compare VENUS REMEDIES With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Marginally Higher, Dow Futures Down by 28 Points(12:30 pm)

Share markets in India are presently trading marginally higher. The BSE Sensex is trading up by 74 points, up 0.2% at 48,877 levels.

Related Views on News

BIOCON Announces Quarterly Results (3QFY21); Net Profit Down 19.7% (Quarterly Result Update)

Jan 25, 2021 | Updated on Jan 25, 2021

For the quarter ended December 2020, BIOCON has posted a net profit of Rs 2 bn (down 19.7% YoY). Sales on the other hand came in at Rs 19 bn (up 5.9% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON Announces Quarterly Results (2QFY21); Net Profit Down 23.9% (Quarterly Result Update)

Oct 29, 2020 | Updated on Oct 29, 2020

For the quarter ended September 2020, BIOCON has posted a net profit of Rs 2 bn (down 23.9% YoY). Sales on the other hand came in at Rs 17 bn (up 11.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON Announces Quarterly Results (3QFY20); Net Profit Up 1.2% (Quarterly Result Update)

Jan 24, 2020 | Updated on Jan 24, 2020

For the quarter ended December 2019, BIOCON has posted a net profit of Rs 2 bn (up 1.2% YoY). Sales on the other hand came in at Rs 17 bn (up 13.5% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON Announces Quarterly Results (2QFY20); Net Profit Down 30.5% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, BIOCON has posted a net profit of Rs 3 bn (down 30.5% YoY). Sales on the other hand came in at Rs 16 bn (up 19.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON Announces Quarterly Results (1QFY20); Net Profit Down 11.5% (Quarterly Result Update)

Jul 29, 2019 | Updated on Jul 29, 2019

For the quarter ended June 2019, BIOCON has posted a net profit of Rs 1 bn (down 11.5% YoY). Sales on the other hand came in at Rs 5 bn (down 57.2% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

More Views on News

Most Popular

India: Recovery Stalled by Vaccine Games?(The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

4 Stocks to Make Your Portfolio Immune to the Second Covid Wave(Profit Hunter)

Apr 6, 2021

Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.

An India Revival Stock I'm Bullish On...(Profit Hunter)

Apr 9, 2021

This could take India to the position of 3rd largest economy.

Why Did the Market Crash on Monday?(Fast Profits Daily)

Apr 13, 2021

In this video, I'll you what I think is the real reason behind yesterday's market crash.

Why the Market Fell Yesterday(Fast Profits Daily)

Apr 6, 2021

In this video, I'll tell you the two reasons why the market fell on Monday and how you can prepare yourself for such events in the future.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Apr 16, 2021 03:36 PM

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES - WOCKHARDT COMPARISON

COMPARE VENUS REMEDIES WITH

MARKET STATS